SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Nymox Pharmaceu...
December 22 2014 - 7:18PM
The securities litigation law firm of Brower Piven, A Professional
Corporation, announces that a class action lawsuit has been
commenced in the United States District Court for the District of
New Jersey on behalf of purchasers of Nymox Pharmaceutical
Corporation ("Nymox" or the "Company") (Nasdaq:NYMX) common stock
during the period between January 31, 2011 and November 2, 2014,
inclusive (the "Class Period"). Investors who wish to become
proactively involved in the litigation have until January 26, 2015
to seek appointment as lead plaintiff.
If you have suffered a loss from investment in Nymox common
stock purchased on or after January 31, 2011 and held through the
revelation of negative information during and/or at the end of the
Class Period, as described below, and would like to learn more
about this lawsuit and your ability to participate as a lead
plaintiff, without cost or obligation to you, please visit our
website at http://www.browerpiven.com/currentsecuritiescases.html.
You may also request more information by contacting Brower Piven
either by email at hoffman@browerpiven.com or by telephone at (410)
415-6616. No class has yet been certified in the above action.
Members of the Class will be represented by the lead plaintiff and
counsel chosen by the lead plaintiff.
If you wish to choose counsel to represent you and the Class,
you must apply to be appointed lead plaintiff and be selected by
the Court. The lead plaintiff will direct the litigation and
participate in important decisions including whether to accept a
settlement and how much of a settlement to accept for the Class in
the action. The lead plaintiff will be selected from among
applicants claiming the largest loss from investment in Company
units during the Class Period. Brower Piven also encourages anyone
with information regarding the Company's conduct during the period
in question to contact the firm, including whistleblowers, former
employees, shareholders and others.
The complaint accuses the defendants of violations of the
Securities Exchange Act of 1934 by virtue of the defendants'
failure to disclose during the Class Period that the measurement of
the effectiveness of the Company's proprietary drug NX-1207 for the
treatment of benign prostatic hyperplastic was so subjective and
patient specific that it provided no scientifically acceptable
basis to predict its effectiveness in other patients. According to
the complaint, following the November 2, 2014 announcement that the
Company's two Phase 3 U.S. studies of NX-1207 had to be halted
because the drug failed to meets its primary endpoints for
efficacy, the value of Nymox shares declined significantly.
Attorneys at Brower Piven have extensive experience in
litigating securities and other class action cases and have been
advocating for the rights of shareholders since the 1980s. If you
choose to retain counsel, you may retain Brower Piven without
financial obligation or cost to you, or you may retain other
counsel of your choice. You need take no action at this time to be
a member of the class.
CONTACT: Charles J. Piven
Brower Piven, A Professional Corporation
1925 Old Valley Road
Stevenson, Maryland 21153
Telephone: 410-415-6616
hoffman@browerpiven.com
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From Apr 2024 to May 2024
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From May 2023 to May 2024